CNS Pharmaceuticals Inc. CEO Highlights Company's Vision at Virtual Investor Conference

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, recently featured its CEO, John Climaco, in the Virtual Investor 'What’s Your Story' Summer Spotlight On-Demand Conference. Climaco discussed his personal journey, leadership vision, and the company's development programs, highlighting CNS Pharmaceuticals' dedication to addressing unmet medical needs in oncology. The webcast of the conference is accessible on virtualinvestorco.com and the Events section of the CNS Pharmaceuticals website.

The company's lead drug candidate, Berubicin, represents a significant advancement in the treatment of aggressive brain cancers, such as glioblastoma multiforme (GBM), by being the first anthracycline to potentially cross the blood-brain barrier. This development is crucial for patients with GBM, a disease with limited treatment options and a poor prognosis. CNS Pharmaceuticals' ongoing research and development efforts aim to bring hope to patients and families affected by these devastating conditions.

For further details on CNS Pharmaceuticals Inc. and its innovative cancer treatments, visit www.CNSPharma.com. Additional news and updates about CNSP can be found in the company’s newsroom at https://ibn.fm/CNSP.